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Abstract
Objective: Since the availability of recombinant human growth hormone (rhGH) all children with
growth hormone deficiency (GHD) living in Belgium are offered rhGH treatment after approval by
a peer–review board. In this study, we evaluated the prevalence and demographic features of child-
hood GHD in Belgium during the period 1986–2001 and we compared them with the data from
other countries.
Methods: Diagnostic, demographic and baseline auxological data of 714 children diagnosed as having
GHD between 1986 and 2001 were retrieved from the database of the Belgian Study Group for Pae-
diatric Endocrinology.
Results: The prevalence of GHD in Belgium was estimated to be 1/5600. The origin of GHD was idio-
pathic (idGHD) in 41% of the patients, congenital (congGHD) in 20% and acquired (acqGHD) in 35%.
During the first 4 years (1986–1989) more patients were classified as idGHD; thereafter the distri-
bution between the three aetiology groups did not change. In all groups, boys outnumbered girls
but this preponderance was especially pronounced in congGHD patients (male:female ¼ 4:1) with
a central malformation that associates an anterior pituitary hypoplasia, a missing, fine or normal
pituitary stalk and an ectopic posterior pituitary. Thirteen percent of the patients with idGHD, 50%
with congGHD and 52% with acqGHD had multiple pituitary deficiencies. Patients with congGHD
were the youngest (mean^S.D. age: 6.5^4.7 years) and were the shortest (23.0^1.3 standard devi-
ation score (SDS)) at the start of rhGH treatment. There was no time trend over the studied period for
age and height at onset of GH therapy.
Conclusion: In Belgium, the prevalence of childhood GHD can be estimated as 1/5600 which is com-
parable to other recent surveys. The yearly number of new patients for the different aetiologies and
the auxological parameters have remained relatively constant over the last 16 years.
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Introduction
Growth hormone deficiency (GHD) is a relatively
uncommon cause of growth retardation and short sta-
ture. The prevalence of childhood GHD reported in the
literature diverges widely varying between 1/3480 and
1/30000 children (1–8).
In 1986, recombinant human growth hormone
(rhGH) was licensed for use in Belgium and since then
supplies of rhGH have been virtually unlimited.
Growth hormone deficiency remains the primary indi-
cation for rhGH treatment and all children with GHD
can be offered optimal treatment. Treatment with
rhGH is reimbursed by the Belgian government, and
until 1993, the use of rhGH was supervised by a minis-
terial commission of experts. After the dismissal of the
ministerial commission, the paediatric endocrinologists
belonging to the Belgian Study Group for Paediatric
Endocrinology (BSGPE) continued to peer-review the
records of patient candidates for rhGH treatment
before applying for its reimbursement.
In the present study, we evaluated the prevalence
and described demographic features of childhood GHD
in Belgium during the period 1986–2001, and we
compared the results with those from other databases
and other countries. The data in this report present a
profile of what could be considered standard diagnostic
practices in Belgium.
Patients and methods
In Belgium, the files of children who are candidates
for treatment with rhGH are discussed by the mem-
bers of the BSGPE using a systematic peer-reviewed
process. The BSGPE includes the Belgian paediatric
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endocrinologists treating children with growth dis-
orders, and represents the seven Belgian universities.
An application for treatment with rhGH to be reim-
bursed by the government is only accepted after a
consensus decision by the majority of the BSGPE
members. Baseline and treatment auxological and bio-
chemical data from the patients approved for rhGH
treatment are stored in the database of the BSGPE.
Signed informed consent forms are obtained from
the parents and the patients if older than 12 years.
From the database of the BSGPE, the data of all chil-
dren (n ¼ 740) diagnosed with GHD between 1986
and 2001 were retrieved. The data of 26 patients were
incomplete and they were not included in the analysis.
GHD was defined by auxological and biological criteria:
height velocity , the 10th or , the 25th centile for
patients with idiopathic and organic GHD respectively,
and peak serum GH levels, measured in the individual
institution’s laboratory, ,10ng/ml during two stimu-
lation tests, usually the glucagon stimulation test and
the insulin tolerance test (9). Sex steroid priming was
carried out for boys aged 10 years or older and for girls
aged 9 years or older if they had a pubertal development
# Genital stage 2 or Breast stage 2, independently of
bone age. In boys, 50mg testosterone propionate were
administered intramuscularly 72h before the GH stimu-
lation test, and the girls received orally 50mg ethinyloes-
tradiol during the three days before the test (9). GHDwas
considered as complete when the maximal GH values at
the two tests were below5ng/ml; GHDwas considered as
partial when the maximal GH values at the two tests
were below 10ng/ml with at least one above 5 ng/ml
(9). Cranial imaging studies, with special emphasis on
the hypothalamo–pituitary region, were performed in
all patients using computed tomography (CT) scanning
or magnetic resonance imaging (MRI). Before 1990,
an MRI was performed in 29% of the patients with
non-acquired GHD, 1990–1993 MRI was performed in
76% and 1994–1997 in 89% of these patients. After
1998, 98% of the patients were evaluated by MRI.
The data collected in this study included aetiology of
GHD, gender, age and height at the start of rhGH treat-
ment, birth weight, parental heights, and associated
pituitary deficiencies. The aetiologies of GHDwere classi-
fied according to the Kabi International Growth Study
aetiology classification list (10). Patients were classified
as idiopathic GHD (idGHD) when no anomaly could be
detected after the performed investigations. Patients
were considered as congenital GHD (congGHD) when a
cerebral developmental anomaly was documented or
when a genetic cause of GHD was found. Patients with
a postnatally acquired cerebral anomaly were classified
as acquired GHD (acqGHD). Height was measured
with a Harpenden stadiometer and expressed as stan-
dard deviation score (SDS) using the Tanner 1966 refer-
ence data (11). Birth weight SDS was calculated using
the Swedish reference data (12). The patients were con-
sidered as small for gestational age (SGA) if birth weight
was below22 SDS. Mid-parental height SDS was calcu-
lated as (father’s height SDS þ mother’s height SDS)/2.
The prevalence of GHD was calculated on the basis of
the Belgian demographic data provided by the National
Institute of Statistics (13). Results are expressed as
means^S.D. or median (range) as indicated. Compari-
sons between the three aetiology groups were carried
out with the chi-squared test, or by ANOVA or
Kruskal–Wallis test. The Jonckheere–Terpstra non-
parametric test was used to test for time trends for
age and height at onset of GH therapy. A P , 0.05
value was considered significant.
Results
Prevalence of GHD
For the studied period, 714 (442 boys) patients with
documented GHD were retrieved from the database of
the BSGPE. Yearly, between 29 and 66 (median 45)
new GHD patients started treatment. In 2001, 386
GHD patients between 0 and 18 years were treated
with rhGH. Consequently, for the Belgian population,
counting about 2.2 million children younger than 18
years, a prevalence (95% confidence interval) of GHD
children of 18 (16–20) per 100 000 (or 1/5600) was
estimated.
Aetiology and gender
The aetiology of GHD and the gender of the patients are
given in Table 1. Forty-one per cent of the patients were
classified as idGHD, 20% as congGHD and 35% as
acqGHD; 4% of the patients had a defined syndrome
with concomitant GHD. The aetiology of the acqGHD
was due, for the majority of the patients (93%), to
cranial tumours and/or cerebral radiotherapy. Boys
outnumbered girls in all groups. The preponderance
of boys was especially pronounced in the patients
with congGHD represented mainly by patients with a
central malformation, most frequently the association
of hypoplastic anterior pituitary, missing, fine or
normal stalk and ectopic posterior pituitary (sex ratio
male:female ¼ 4).
Figure 1 shows the 4-yearly evolution of new
patients with GHD. During the first 4 years (1986–
1989) more patients were classified as idGHD. The
yearly number of new patients with congGHD and
acqGHD remained relatively stable over the whole
period.
Severity of GHD and associated pituitary
deficiencies
Of the patients with idGHD, 37% had complete GHD
while 78% of the patients with congGHD and 62% of
the patients with acqGHD were diagnosed as complete
GHD (P , 0.001).
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Table 2 shows the associated pituitary deficiencies.
Fifty per cent of the patients with congGHD and 52%
with acqGHD had other hormonal deficiencies, while
these were present only in 13% of the patients with
idGHD (P , 0.01). Thyrotrophin (TSH) deficiency was
the most frequent pituitary deficiency associated with
GHD. Patients with congGHD and acqGHD had an
adrenocorticotrophin (ACTH) deficiency more fre-
quently than patients with idGHD (P , 0.01). In the
three groups, about half of the patients with multiple
pituitary deficiencies had luteinizing hormone/follicle-
stimulating hormone (LH/FSH) deficiency. More than
half of the patients with multiple acqGHD had an
associated antidiuretic (ADH) deficiency.
Age and height at onset of therapy, birth
weight and parental height
Table 3 shows the age and height at onset of rhGH
therapy, birth weight and parental height for the
three aetiology groups. For the whole group of patients,
rhGH therapy was started at the median age of
9.1 years (range 0.0–27.3 years). The patients with
congGHD were younger than the patients in the other
groups (P , 0.001). In the three groups, no differences
were found for the age at onset of GH therapy between
patients with partial and complete GHD. In the patients
with idGHD and congGHD rhGH treatment was started
when a serious height deficit (22.8^0.9 SDS and
23.0^1.3 SDS respectively) was already present.
Figure 1 Four-yearly evolution of the number of new patients with
idGHD (black bars), congGHD (dark grey bars) and acqGHD
(light grey bars).
Table 1 Aetiology of GHD. The numbers of patients in the congenital and the acquired GHD groups (both belonging to the organic
GHD group) were further subdivided depending on their specific aetiology.
Group






subgroup % of total Group Subgroup
Idiopathic GHD 296 41 1.5
Organic GHD
Congenital form 142 20 3.0





Acquired GHD 245 35 1.2
Cranial tumour of the pituitary–hypothalamus area4 77
Irradiated 37
Non-irradiated 40





Treatment for malignancy outside the cranium 31
Acute lymphatic leukaemia 25
Lymphoma and other tumours outside the cranium6 6
Other causes of acquired GHD7 18
Syndromes with concomitant GHD 31 4 2.9
Total 714 1.6
1 Hypoplastic anterior pituitary–missing stalk, fine stalk or normal stalk–ectopic posterior pituitary.
2 Septo-optic dysplasia (n ¼ 8), mid-line palatal cleft (n ¼ 5), arachnoid cyst (n ¼ 4), congenital hydrocephalus (n ¼ 9), empty sella syndrome (n ¼ 5),
solitary central maxillary incisor syndrome (n ¼ 1), schizencephalia (n ¼ 1), encephaloclastic lesion (n ¼ 1), Rathke’s cyst (n ¼ 1).
3 Syndromes with congenital GHD: q18 deletion (n ¼ 1), 46,XX/46,XX del(20) (p122) (n ¼ 1); congenital toxoplasmosis (n ¼ 1).
4 Craniopharyngioma (n ¼ 56), germinoma (n ¼ 12), adenoma (n ¼ 5), chordoma (n ¼ 1), choriocarcinoma (n ¼ 1), hypothalamic tumour (n ¼ 2).
5 Medulloblastoma (n ¼ 47), astrocytoma (n ¼ 24), glioma (n ¼ 15), ependymoma (n ¼ 7), rhabdomyosarcoma (n ¼ 12), osteosarcoma (n ¼ 1), gangliocy-
toma (n ¼ 2), glioblastoma (n ¼ 1), meningioma (n ¼ 1), mesencephalic tumour (n ¼ 1), neurocytoma (n ¼ 1), papilloma (n ¼ 1), primitive neuroectodermal
turmour (n ¼ 1), retinoblastoma (n ¼ 2), teratoma (n ¼ 2), other (n ¼ 1).
6 Lymphoma (n ¼ 4), neuroblastoma/TBI (n ¼ 1), hepatoblastoma (n ¼ 1).
7 Head trauma (n ¼ 8), histiocytosis (n ¼ 6), enlarged stalk (n ¼ 1), CNS infection (n ¼ 1), Total body irradiation for thalassaemia major (n ¼ 1), Blackfan-
Diamond (n ¼ 1).
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Respectively, 90 and 86% of the patients with idGHD
and congGHD were smaller than the 3rd percentile at
the start of rhGH treatment, whereas only 35% of the
patients with acqGHD were smaller than the 3rd per-
centile (P , 0.001). Age and height at onset of rhGH
therapy did not change significantly during the studied
period (data not shown).
Birth weight was significantly below the population
mean (P , 0.001) in the patients with idGHD and
congGHD. Respectively, 18, 11 and 4% of the patients
with idGHD, congGHD and acqGHD were considered
as SGA (P , 0.001). Mid-parental height SDS of the
patients with congGHD and acqGHD was comparable
to the general population. In contrast, patients with
idGHD had a mid-parental height below the normal
population (P , 0.001); 8% of the patients in this
latter group had a mid-parental height below the 3rd
percentile while this was the case in only 3 and 1%
of the patients with congGHD and acqGHD respectively.
We did not find any major differences between boys
and girls for the parameters detailed above except
that in girls with congGHD and acqGHD, rhGH treat-
ment was initiated at a younger age than in boys: 4.9
versus 7.2 years, and 10.2 versus 11.4 years
(P ¼ 0.003) respectively.
Figure 2 shows that 58% of the patients with congGHD
started treatment before the age of 10 years; there was a
bimodal distribution for the age at onset of rhGH therapy
in childrenwith idGHD,with a first peak around the age of
4–5 years and another peak around the age of 10–12
years. In the patients with acqGHD, the age at onset of
therapy ranged between 8 and 15 years.
Discussion
Based on data from children diagnosed and treated for
GHD by the members of the BSGPE, we estimated the
prevalence of childhood GHD in Belgium in 2001 to
be 1/5600. This number is comparable to the obser-
vations of the Dutch Growth Foundation (1/5000),
using a comparable method to evaluate the prevalence
of GHD (3). Our prevalence is somewhat lower than
that reported in the United Kingdom (1/4018) (2)
and in the state of Utah in the USA (1/3480) (1),
Table 2 Number of patients with multiple pituitary hormone deficiencies (MPHD) and distribution of other pituitary deficiencies for the
different aetiologies.
MPHD
TSH/MPHD ACTH/MPHD LH FSH/MPHD ADH/MPHD
Cause of GHD n % (%) (%) (%) (%)
IdGHD (n ¼ 296) 38 13 82 34 48 5
CongGHD (n ¼ 142) 71 50 93 68 49 11
AcqGHD (n ¼ 245) 127 52 87 69 54 57
Table 3 Age and height at onset of GH therapy, birth weight and














IdGHD 8.6^4.4 22.8^0.9 21.0^1.2 20.4^1.2
CongGHD 6.5^4.7 23.0^1.3 20.7^1.0 0.1^1.0
AcqGHD 10.9^3.2 21.4^1.1 20.3^1.0 0.2^0.9
Figure 2 Age at onset of GH therapy in the three main groups:
(a) idGHD, (b) congGHD, (c) acqGHD.
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while it is higher than in Australia (1/6757) (4), Japan
(1/6797) (5) and China (1/8646) (6). As pointed out
by Lindsay and colleagues (1), the true prevalence of
GHD can only be derived from large-scale screening
studies. In their survey evaluating 114881 elementary
school children, the presence of GHD was found in 16
previously unrecognized children out of 555 with
short stature (,3rd percentile) and poor growth rates
(,5 cm/year). Seventeen children were already
known to have GHD. Our prevalence number, based
on patients referred to paediatric endocrinologists,
probably underestimates the true number of GHD chil-
dren, and a population-based screening is needed to
reveal the true prevalence of childhood GHD.
In our series of childrenwith GHD, 41%were classified
as idGHD, 20% as congGHD and 35% as acqGHD. The
distribution among the three main diagnostic groups of
GHD has remained relatively constant over the past
16 years. This is in agreement with the results reported
by Cutfield et al. for patients enrolled into KIGS (14).
However, the distribution amongst the various aetiolo-
gies in our study differs from that reported in other
countries or databases. The percentage of idGHD is
lower than that observed in other surveys where the
percentage of idGHD patients ranges from 65 to 85%
(15–17). In contrast, in our series more patients were
diagnosed as congGHD. These discordances can partly
be explained by classification differences: in less recent
studies, a number of patients with hypothalamo–pitu-
itary malformations who have not been evaluated by a
cranial MRI may still have been classified in the idGHD
group. Indeed, as the diagnostic procedures progress,
more abnormalities by imaging or at the gene level will
be found in patients heretofore classified as idGHD. In
addition, possible gene defects were not systematically
searched for in our idGHD patients. For these reasons,
the number of patients classified as idGHD will decrease
in the future. Another possible difference between this
studyand others is the greater proportion of peripubertal
patients with constitutional delay of growth and puberty
andwith low GH secretion included in the other surveys.
This latter hypothesis is supported by the finding that the
age at onset of rhGH therapy in the idGHD group is lower
in Belgium (8.5 years) compared with the patients
enrolled, for example, into KIGS (10.3 years) (18).
In line with the data in the literature, boys outnum-
bered girls in all aetiology groups (4, 15, 17, 18). In
patients with idGHD, the ratio of males to females
in our study is, however, lower than that reported in
other studies (1.5 in Belgium versus 2.5 (USA) (15),
3.1 (Sweden) (17), 1.9 (UK) (17), 2.0 (France) (17),
2.6 (Germany) (17) and 2.0 (KIGS) (18)). This is also
the case in patients with acqGHD (1.2 in Belgium
versus 2.1 (USA) (15) and 1.5 (KIGS) (18)). In contrast,
the ratio of males to females is higher in the Belgian
patients with congGHD (3.0 versus 1.3 (USA) (15)
and 1.7 (KIGS) (18)) especially in patients with a cen-
tral malformation that associates an anterior pituitary
hypoplasia, a missing, fine or normal pituitary stalk
and an ectopic posterior pituitary. In other studies
this ratio is not reported.
Although patients with congGHD have GHD from
birth, rhGH treatment was started at a mean age of
6.5^4.7 years. The delay in starting rhGH therapy
may be related to the degree of GH insufficiency associ-
ated with the various congenital conditions (19) and/or
the delay in diagnosis which depends on the moment of
referral to the paediatric endocrinologist. In the idGHD
group a bimodal distribution for the age at onset of
rhGH therapy is observed with peaks in mid and late
childhood. It remains to be shown whether these two
cohorts correspond to different pathophysiological
mechanisms. In contrast, the age range in the acqGHD
group appears broader, from 8 to 15 years. These obser-
vations have also been reported by August et al. (15) and
by Cutfield et al. for patients in the KIGS database (14).
In the patients with idGHD, the age at onset of rhGH
therapy (8.5 years) is lower than in the patients included
in KIGS (10.3 years) (18) or in France (11.1 years) (17)
while it is comparable to that of other countries such as
the United Kingdom and Germany (8.2 years for the
2 countries) (17). These differences can be due to vari-
ations in diagnostic procedures between countries
(e.g. sex steroid priming) and/or between the considered
time periods in the evaluation of short children for GHD.
For the congGHD and acqGHD, the age at onset of rhGH
therapy is comparable to other series (4, 15, 18). The
age at onset of rhGH therapy did not change signifi-
cantly in Belgium between 1986 and 2001 for the
three groups. This is in line with the data for the patients
with idGHD included in the KIGS database between
1987 and 1997 (16).
In the patients with idGHD and congGHD rhGH treat-
ment was started when a serious height deficit was
already present. In patients with idGHD, height at
onset of GH therapy (22.8 SDS) is comparable to that
reported in KIGS (22.5 SDS) (18) but lower than in
Sweden for example (22.3 SDS) (17). In patients
with congGHD (23.0 SDS) and acqGHD (21.4 SDS)
mean height at onset is comparable to that reported
in KIGS (18). In children with idGHD, Cutfield et al.
reported a reduction in the height deficit at the start
of treatment in patients with idGHD and acqGHD of
0.4 and 0.6 SDS respectively over a period of 10 years
(1987–1996) (14). This was not the case in our study.
In line with the data reported in KIGS (18), we
observed that the mean birth weight was lower than
the population mean in the children with congGHD
(20.7 SDS) and idGHD (21.0 SDS). These data are
in line with data suggesting that GH plays a role in pre-
natal growth (20, 21). In agreement with the data
from the literature (14, 18), mean mid-parental
height was below the population mean in the patients
with idGHD, whereas parental height was normal in
the other groups. This finding suggests that patients
with familial short stature can present (transient)
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GHD (22), underlining the need for re-evaluation of GH
secretion in adulthood (9).
In conclusion, we estimated the prevalence of child-
hood GHD in Belgium to be 1/5600. Over the past 16
years, the yearly number of new patients and the aux-
ological parameters remained relatively constant. In
comparison with the data from other surveys and
countries we observed a higher percentage of children
with congenital GHD. However, any comparison with
other publications is difficult as diagnostic modalities
(e.g. MRI, genetic analyses, sex steroid priming) for
GHD not only vary between countries, but also between
the considered time periods. Moreover, the occurrence
of acqGHD in oncologic patients may be related to the
tumour treatment which also varies between countries
and time periods. Nevertheless, our data underline the
need for an accurate cranial MRI evaluation in all chil-
dren with GHD in order to detect those with central
malformations, and the need for genetic analysis in
those patients suspected of genetic causes of GHD. As
children with congGHD and idGHD are still diagnosed
relatively late with a severe height deficit, growth of
all children, especially those with short stature,
should be monitored very carefully, and timely referral
to a paediatric endocrinologist with experience in
growth disorders should be considered.
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